Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis

Int J Cancer. 2012 Jun 1;130(11):2685-92. doi: 10.1002/ijc.26301. Epub 2011 Sep 14.

Abstract

Osteopontin (OPN) has been implicated in tumor development and progression for several years. However, the prognostic value of OPN overexpression in patients with hepatocellular carcinoma (HCC) remains controversial. We performed a meta-analysis to assess the relationship between OPN overexpression and clinical outcome of HCC. A meta-analysis of seven studies (1,158 patients) was carried out to evaluate the association between OPN and overall survival (OS) and disease-free survival (DFS) in HCC patients. The correlation between OPN and tumor vascular invasion or other invasion-related parameters was also assessed. Data were synthesized with random effect model of DerSimonian and Laird, hazard ratio (HR) or odds ratio (OR) with its 95% confidence interval (CI) was used as the effect size estimate. Our analysis results indicated that high OPN expression predicted poor OS (HR: 1.37, 95% CI: 1.21-1.55) and DFS (HR: 1.62, 95% CI: 1.24-2.11) of HCC. OPN overexpression tended to be associated with the presence of tumor vascular invasion (OR: 1.93, 95% CI: 0.97-3.84) and advanced tumor grade (OR: 1.74, 95% CI: 0.95-3.18). By this study, we conclude that OPN overexpression indicates a poor prognosis for patients with HCC, it may also have predictive potential for HCC invasion and metastasis.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Hepatocellular / blood
  • Carcinoma, Hepatocellular / chemistry
  • Carcinoma, Hepatocellular / mortality*
  • Carcinoma, Hepatocellular / pathology
  • Disease-Free Survival
  • Humans
  • Liver Neoplasms / blood
  • Liver Neoplasms / chemistry
  • Liver Neoplasms / mortality*
  • Liver Neoplasms / pathology
  • Middle Aged
  • Neoplasm Invasiveness
  • Neoplasm Staging
  • Osteopontin / analysis*
  • Osteopontin / physiology
  • Prognosis
  • Publication Bias

Substances

  • Osteopontin